Receptor activator of NF-κB ligand and osteoprotegerin regulate proinflammatory cytokine production in mice

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 3799-3805

  Maruyama, Kenta ^a   Takada, Yasunari ^a   Ray, Neelanjan ^a   Kishimoto, Yukiko ^b   Penninger, Josef M ^c   Yasuda, Hisataka ^b   Matsuo, Koichi ^a  

^a KEIO UNIVERSITY   (Japan)

^b Oriental Yeast Co Ltd   (Japan)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN C FOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DOWN REGULATION; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SALMONELLA ENTERICA; SALMONELLOSIS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 33748513678     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.3799     Document Type: Article

References (38)

1. Wong, B. R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F. S. Bartlett III, W. N. Frankel, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272: 25190-25194.
2. Anderson, D. M., E. Maraskovsky, W. L. Billingsley, W. C. Dougall, M. E. Tometsko, E. R. Roux, M. C. Teepe, R. F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.
3. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602.
4. Simonet, W. S., D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang, R. Luthy, H. Q. Nguyen, S. Wooden, L. Bennett, T. Boone, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
5. Yasuda, H., N. Shima, N. Nakagawa, S. I. Mochizuki, K. Yano, N. Fujise, Y. Sato, M. Goto, K. Yamaguchi, M. Kuriyama, et al. 1998. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337.
6. Matsuo, K., D. L. Galson, C. Zhao, L. Peng, C. Laplace, K. Z. Wang, M. A. Bachler, H. Amano, H. Aburatani, H. Ishikawa, and E. F. Wagner. 2004. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279: 26475-26480.
7. Kong, Y. Y., H. Yoshida, I. Sarosi, H. L. Tan, E. Timms, C. Capparelli, S. Morony, A. J. Oliveira-dos-Santos, G. Van, A. Itie, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
8. Dougall, W. C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M. E. Tometsko, C. R. Maliszewski, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev. 13: 2412-2424.
9. Li, J., I. Sarosi, X. Q. Yan, S. Morony, C. Capparelli, H. L. Tan, S. McCabe, R. Elliott, S. Scully, G. Van, et al. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97: 1566-1571.
10. Lomaga, M. A., W. C. Yeh, I. Sarosi, G. S. Duncan, C. Furlonger, A. Ho, S. Morony, C. Capparelli, G. Van, S. Kaufman, et al. 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13: 1015-1024.
11. Naito, A., S. Azuma, S. Tanaka, T. Miyazaki, S. Takaki, K. Takatsu, K. Nakao, K. Nakamura, M. Katsuki, T. Yamamoto, and J. Inoue. 1999. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4: 353-362.
12. Franzoso, G., L. Carlson, L. Xing, L. Poljak, E. W. Shores, K. D. Brown, A. Leonardi, T. Tran, B. F. Boyce, and U. Siebenlist. 1997. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11: 3482-3496.
13. Wang, Z. Q., C. Ovitt, A. E. Grigoriadis, U. Möhle-Steinlein, U. Rüther, and E. F. Wagner. 1992. Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741-744.
14. Grigoriadis, A. E., Z. Q. Wang, M. G. Cecchini, W. Hofstetter, R. Felix, H. A. Fleisch, and E. F. Wagner. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448.
15. Matsuo, K., J. M. Owens, M. Tonko, C. Elliott, T. J. Chambers, and E. F. Wagner. 2000. Fos11 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24: 184-187.
16. Asagiri, M., K. Sato, T. Usami, S. Ochi, H. Nishina, H. Yoshida, I. Monta, E. F. Wagner, T. W. Mak, E. Serfling, and H. Takayanagi. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202: 1261-1269.
17. Bucay, N., I. Sarosi, C. R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H. L. Tan, W. Xu, D. L. Lacey, et al. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12: 1260-1268.
18. Mizuno, A., N. Amizuka, K. Irie, A. Murakami, N. Fujise, T. Kanno, Y. Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, et al. 1998. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247: 610-615.
19. Wong, B. R., R. Josien, S. Y. Lee, B. Sauter, H. L. Li, R. M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186: 2075-2080.
20. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554.
21. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145.
22. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
23. Gulig, P. A., and R. Curtiss, 3rd. 1987. Plasmid-associated virulence of Salmonella typhimurium. Infect. Immun. 55: 2891-2901.
24. Zhao, C., N. We, Y. Takada, K. Shimoda, T. Miyamoto, T. Nishiwaki, T. Suda, and K. Matsuo. 2006. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4: 111-121.
25. Miyamoto, T., O. Ohneda, F. Arai, K. Iwamoto, S. Okada, K. Takagi, D. M. Anderson, and T. Suda. 2001. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 98: 2544-2554.
26. Ray, N., M. Kuwahara, Y. Takada, K. Maruyama, T. Kawaguchi, H. Tsubone, H. Ishikawa, and K. Matsuo. 2006. c-Fos suppresses systemic inflammatory response to endotoxin. Int. Immunol. 18:671-677.
27. Kobayashi, K., L. D. Hernandez, J. E. Galán, C. A. Janeway, Jr., R. Medzhitov, and R. A. Flavell. 2002. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202.
28. Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5: 373-379.
29. Kinjyo, I., T. Hanada, K. Inagaki-Ohara, H. Mori, D. Aki, M. Ohishi, H. Yoshida, M. Kubo, and A. Yoshimura. 2002. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17: 583-591.
30. Nakagawa, R., T. Naka, H. Tsutsui, M. Fujimoto, A. Kimura, T. Abe, E. Seki, S. Sato, O. Takeuchi, K. Takeda, et al. 2002. SOCS-1 participates in negative regulation of LPS responses. Immunity 17: 677-687.
31. Itoh, K., N. Udagawa, K. Kobayashi, K. Suda, X. Li, M. Takami, N. Okahashi, T. Nishihara, and N. Takahashi. 2003. Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J. Immunol. 170: 3688-3695.
32. Sato, N., N. Takahashi, K. Suda, M. Nakamura, M. Yamaki, T. Ninomiya, Y. Kobayashi, H. Takada, K. Shibata, M. Yamamoto, et al. 2004. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1α. J. Exp. Med. 200: 601-611.
33. Okahashi, N., A. Sakurai, I. Nakagawa, T. Fujiwara, S. Kawabata, A. Amano, and S. Hamada. 2003. Infection by Streptococcus pyogenes induces the receptor activator of NF-κB ligand expression in mouse osteoblastic cells. Infect. Immun. 71: 948-955.
34. Zhang, X., J. E. Aubin, T. H. Kim, U. Payne, B. Chiu, and R. D. Inman. 2004. Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. Infect. Immun. 72: 7183-7189.
35. Kanamaru, F., H. Iwai, T. Ikeda, A. Nakajima, I. Ishikawa, and M. Azuma. 2004. Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells. Immunol. Lett. 94: 239-246.
36. 2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J. Biol. Chem. 280: 41700-41706.
37. Tiegs, G., J. Barsig, B. Matiba, S. Uhlig, and A. Wendel. 1994. Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J. Clin. Invest. 93: 2616-2622.
38. Basu, S., A. R. Dunn, M. W. Marino, H. Savoia, G. Hodgson, G. J. Lieschke, and J. Cebon. 1997. Increased tolerance to endotoxin by granulocyte-macrophage colony-stimulating factor-deficient mice. J. Immunol. 159: 1412-1417.